10. Guardant Health, Inc. (NASDAQ:GH)
Number of Hedge Fund Holdings: 28
Year-to-Date Performance as of January 30: 63.47%
Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in liquid biopsy tests for early cancer detection and treatment guidance. The company’s flagship product, Guardant360, helps oncologists analyze tumor DNA from blood samples and enables targeted cancer therapies. Guardant Health, Inc. (NASDAQ:GH) collaborates with pharmaceutical firms, hospitals, and research institutions to advance personalized cancer treatment and improve patient outcomes.
Guardant Health, Inc. (NASDAQ:GH) stock has experienced significant gains year to date, driven by a series of positive developments that have bolstered investor confidence and underscored the company’s strong market position. One of the primary catalysts for the stock’s performance has been the company’s preliminary Q4 revenue, which came in at approximately $200 million, surpassing the analyst estimate of $188.9 million. This strong revenue performance is a testament to the growing adoption of the company’s liquid biopsy tests and the expanding market for precision oncology solutions. The company also reported a full-year revenue of approximately $737 million, exceeding the estimated $723.9 million, further solidifying its financial health and growth trajectory.
Another significant factor contributing to Guardant Health, Inc.’s (NASDAQ:GH) stock’s rise is the expansion of Medicare coverage for Guardant Reveal, the company’s liquid biopsy test for monitoring disease recurrence in patients with colorectal cancer. This expansion builds on the existing coverage for early post-surgical testing and significantly broadens the patient population that can benefit from the test. This, in turn, is expected to drive higher adoption rates and contribute to the company’s financial growth.
